ARID1A and neoplasm: ARID1A-deficient ovarian cells present with a microsatellite instability (MSI) genomic signature with an increased mutational burden, along with elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression, thereby providing a rationale to explore the role of immunotherapy in this setting.